FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Frederique Bigonzi

Research Profile

Chemicals & Drugs

Disorders

Procedures

Phenomena

Recurrence

Concepts & Ideas

Co-author Network

Publications

TOP 3
Jack L Martin; Edward T A Fry; Ger-Jan Sanderink; Trevor H Atherley; Colette M Guimart; Paul J Chevalier; Marie-Laure Ozoux; Catherine E Pensyl; Frederique Bigonzi
Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.
Marc Cohen; Andrea Alberto Conti; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Maria Krzeminska-Pakula; Nicolas Danchin; Harvey D White; Jose Santopinto; Frederique Bigonzi; Carole Hecquet; Luc Vittori
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Marc Cohen; Pierre Théroux; Steven Borzak; Martin J Frey; Harvey D White; W Van Mieghem; Fred Senatore; Joy Lis; Robin Mukherjee; Kathy Harris; Frederique Bigonzi
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Frederique Bigonzi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Jack L Martin; Edward T A Fry; Ger-Jan Sanderink; Trevor H Atherley; Colette M Guimart; Paul J Chevalier; Marie-Laure Ozoux; Catherine E Pensyl; Frederique Bigonzi
Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2004;61(2):163-70.
2003: Marc Cohen; Andrea Alberto Conti; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Maria Krzeminska-Pakula; Nicolas Danchin; Harvey D White; Jose Santopinto; Frederique Bigonzi; Carole Hecquet; Luc Vittori
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Journal of the American College of Cardiology 2003;42(8):1348-56.
2002: Marc Cohen; Pierre Théroux; Steven Borzak; Martin J Frey; Harvey D White; W Van Mieghem; Fred Senatore; Joy Lis; Robin Mukherjee; Kathy Harris; Frederique Bigonzi
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
American heart journal 2002;144(3):470-7.
2002: Keith A A Fox; Elliott M Antman; Marc Cohen; Frederique Bigonzi
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
The American journal of cardiology 2002;90(5):477-82.
2002: Elliott M Antman; Hans W Louwerenburg; Hubert F Baars; Jan C L Wesdorp; Bas Hamer; Jean-Pierre Bassand; Frederique Bigonzi; Ghislaine Pisapia; C Michael Gibson; Hein Heidbuchel; Eugene Braunwald; Frans Van de Werf
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
Circulation 2002;105(14):1642-9.
2001: Scott Darrell Berkowitz; Sandra S Stinnett; Marc Cohen; GJ Fromell; Frederique Bigonzi
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
The American journal of cardiology 2001;88(11):1230-4.
2001: Allan M Ross; P Molhoek; Conor F Lundergan; M Knudtson; YC Draoui; L Regalado; V Le Louer; Frederique Bigonzi; W Schwartz; E de Jong; KS Coyne
Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
Circulation 2001;104(6):648-52.
2000: Marc Cohen; Frans Maritz; Andrea Alberto Conti; N Danchin; Ari Timerman; Kurt Huber; Enrique P Gurfinkel; H White; Keith A A Fox; Luc Vittori; V Le Louer; Frederique Bigonzi
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Journal of thrombosis and thrombolysis 2000;10(3):241-6.
2000: Marc Cohen; Elliott M Antman; Enrique P Gurfinkel; Alexander G G Turpie; J Furst; Frederique Bigonzi; David Radley
Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction.
The American journal of cardiology 2000;86(5):553-6, A9.
2000: Shaun G Goodman; Marc Cohen; Frederique Bigonzi; Enrique P Gurfinkel; David Radley; V Le Iouer; GJ Fromell; C Demers; Alexander G G Turpie; Robert M Califf; Keith A A Fox; Anatoly Langer
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
Journal of the American College of Cardiology 2000;36(3):693-8.
2000: Keith A A Fox; S Goodman; Frederique Bigonzi; V Le Louer; Marc Cohen
Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events.
European heart journal 2000;21(17):1433-9.
1998: Marc Cohen; C Demers; Enrique P Gurfinkel; Alexander G G Turpie; GJ Fromell; S Goodman; Anatoly Langer; Robert M Califf; Keith A A Fox; J Premmereur; Frederique Bigonzi
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
The American journal of cardiology 1998;82(5B):19L-24L.
1997: Marc Cohen; C Demers; Enrique P Gurfinkel; Alexander G G Turpie; GJ Fromell; S Goodman; Anatoly Langer; Robert M Califf; Keith A A Fox; J Premmereur; Frederique Bigonzi
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
The New England journal of medicine 1997;337(7):447-52.